Yttrium-90 radioembolization for the treatment of unresectable liver cancer: Results of a single center

Abstract

ÖZETAmaç: Çalışmamızda kemoterapiden fayda görmeyen, rezeke edilemeyen karaciğer kanserlerinde yttrium-90 (Y-90) resin mikrosfer radyoembolizasyon terapisinin etkinliğinin ortaya konması amaçlanmıştır.Yöntemler: Çalışmaya radyoembolizasyon tedavisi uygulanan, rezeke edilemeyen primer veya gastrointestinal sistemden metastatik 55 hasta dahil edilmiştir. Üç hasta ön değerlendirme anjiografisi sonrasında çalışma dışı bı-rakılmıştır. Kalan 52 hastanın 13'ü (%23.6) hepatosellü-ler karsinoma, 39'u (%76.4) metastatik karaciğer kanseri hastasıdır. Elli iki hasta radyoembolizan tedavi görmüştür. Her hastaya verilen tedavi, Solid Tümörlerde Tedaviye Yanıt Kritirleri'ne (RECIST) göre değerlendirilmiş ve tüm sürvi olasılığı Kaplan-Meier metoduna ile grafik olarak gösterilmiştir.Bulgular: Y-90 tedavisi sonrası 47 hasta takip edilebilmiştir. Hastaların %57'sinde klinik fayda yanıtı alınmış, %43'ünde hastalık progresyon göstermiştir. Hastaların medyan hepatik progresyonsuz survi süresi 3.4 ay (%95 confidence interval (ci): 1.4-5.3), tüm sürvi süresi 11.3 (%95 confidence interval (ci): 8.7-14.03) olarak saptanmıştır.Sonuç: Bu çalışma Y-90 resin mikrosfer radyoembolizan tedavinin rezeke edilemeyen karaciğer kanseri hastalarında etkin olduğunu ortaya koymaktadır.Anahtar kelimeler: Yttrium-90, radyoembolizasyon, anjiografi, karaciğer kanseri ABSTRACT Objective: To determine the effects of yttrium-90 (Y-90) resin microsphere radioembolization therapy on patients with unresectable liver cancer who do not benefit from chemotherapy. Methods:Fifty-five patients underwent radioembolization therapy included in the study whose had unresectable primary or metastatic liver cancer originating from the gastrointestinal tract. Three were excluded from the study after pre-evaluation angiography. Thirteen (23.6%) of the remaining 52 patients had hepatocellular carcinoma and 39 (76.4%) had metastatic liver cancer. Fifty-two patients underwent Y-90 radioembolization treatment. Each patient's response to the administered treatment was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) and the overall probability of survival was displayed graphically by the Kaplan-Meier method.Results: After Y-90 therapy, 47 patients were follow-up. While 57% of the patients responded to treatment as clinical benefit, the disease progressed in 43%. The median hepatic progression-free survival time of the patients was 3.4 months (95% confidence interval (ci):1.4-5.3) and the overall survival time was 11.3 months (95%, CI:8.7-14.03). Conclusion:This study emphasizes that Y-90 resin microsphere radioembolization treatment is effective in patients with unresectable liver cancer.

The Effect of Transarterial Y-90 Microsphere Treatment on Biochemical Parameters in Liver Tumors

“…In addition, liver is a frequent site of metastasis for many common malignancies such as breast and colon (2)(3)(4). The prognosis of unresectable liver cancer is poor (5). Treatment options include chemotherapy, transarterial chemoembolization, regional radiotherapy, radiofrequency ablation, transarterial radioembolization (TARE) and transplantation (5).…”

“…The prognosis of unresectable liver cancer is poor (5). Treatment options include chemotherapy, transarterial chemoembolization, regional radiotherapy, radiofrequency ablation, transarterial radioembolization (TARE) and transplantation (5).…”